Esperion Therapeutics, Inc.
ESPR
$3.78
$0.123.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.13% | 79.45% | -166.30% | 62.16% | 28.43% |
| Total Depreciation and Amortization | 0.00% | 170.00% | -- | 350.00% | 0.00% |
| Total Amortization of Deferred Charges | 89.49% | 85.52% | 59.95% | -60.09% | 4.68% |
| Total Other Non-Cash Items | -15.28% | -88.58% | -64.20% | -49.82% | -58.73% |
| Change in Net Operating Assets | 268.82% | -426.35% | 155.17% | -638.76% | -288.78% |
| Cash from Operations | 87.87% | -336.11% | -142.04% | 5.68% | -82.79% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,909.79% | -68.58% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -100.00% | -28.60% | 3,276.86% | -124.28% |
| Cash from Financing | 217.34% | 109.49% | -108.28% | 682.73% | -110.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.32% | 23.41% | -120.87% | 100.14% | -88.63% |